Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C.
Biotech Research and Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
In Vivo. 2024 Nov-Dec;38(6):3131-3137. doi: 10.21873/invivo.13799.
BACKGROUND/AIM: Most nontraumatic subarachnoid hemorrhages (SAHs) are caused by ruptured saccular aneurysms, often resulting in a devastating clinical event characterized by high mortality and significant morbidity among survivors. Numerous studies have confirmed the neuroprotective effects of the molecular hydrogen due to its unique biological properties.
We present the case of a 44-year-old female with aneurysmal SAH with rheumatoid arthritis (RA) and newly diagnosed systemic lupus erythematosus (SLE), complicated by acute ischemic infarction. Despite surgical, pharmacological and non-pharmacological interventions, including embolization of the aneurysm, immunosuppressant, non-vitamin K antagonist oral anticoagulant (NOAC), and plasmapheresis, loss of consciousness continued. The patient began daily treatment with hydrogen capsules, resulting in increased in Treg cells, Breg cells, increased TIM3+ expression on Tc cells, and the conversion of anti-dsDNA from positive to negative. Her clinical symptoms stabilized without adverse effects.
This case highlights the potential benefits of molecular hydrogen therapy in managing aneurysmal SAH with underlying autoimmune disease, warranting further research.
背景/目的：大多数非创伤性蛛网膜下腔出血（SAH）是由破裂的囊状动脉瘤引起的，常导致严重的临床事件，幸存者死亡率高，发病率高。许多研究证实了由于其独特的生物学特性，分子氢具有神经保护作用。
我们报告了一例 44 岁女性患有伴有类风湿关节炎（RA）和新诊断的系统性红斑狼疮（SLE）的动脉瘤性 SAH，并发急性缺血性梗死。尽管进行了手术、药物和非药物干预，包括动脉瘤栓塞、免疫抑制剂、非维生素 K 拮抗剂口服抗凝剂（NOAC）和血浆置换，但仍持续失去意识。患者开始每天服用氢胶囊，导致 Treg 细胞、Breg 细胞增加，Tc 细胞上 TIM3+表达增加，抗 dsDNA 由阳性转为阴性。她的临床症状稳定，没有不良反应。
本病例强调了分子氢治疗在管理伴有自身免疫性疾病的动脉瘤性 SAH 中的潜在益处，值得进一步研究。
